Department of Surgery, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Mail Code: L223, Portland, OR 97239, USA.
Department of Surgery, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Mail Code: L223, Portland, OR 97239, USA.
Surg Clin North Am. 2024 Jun;104(3):657-671. doi: 10.1016/j.suc.2023.12.005. Epub 2024 Jan 3.
The past few decades have seen significant advancements in the medical management of both ulcerative colitis (UC) and Crohn's disease (CD). The previous dependence on steroids is no longer an acceptable strategy following the Food and Drug Administration approval for several new classes of medication. These medications include aminosalicylates, immunomodulators, biologics, and oral targeted small-molecule inhibitors. This article highlights several key trials and discusses modern treatment paradigms for both UC and CD based on disease severity.
在过去的几十年中,溃疡性结肠炎 (UC) 和克罗恩病 (CD) 的医学治疗取得了重大进展。在食品和药物管理局批准了几种新类别的药物后,以前依赖类固醇的策略不再是可以接受的策略。这些药物包括氨基水杨酸盐、免疫调节剂、生物制剂和口服靶向小分子抑制剂。本文重点介绍了几项关键试验,并根据疾病严重程度讨论了 UC 和 CD 的现代治疗模式。